Janux Therapeutics shareholders elect three Class I directors, ratify EY

Janux Therapeutics, Inc.

David Campbell, Ron Barrett, and Winston Kung elected Class I directors with >42M votes each.
Ernst & Young ratified as auditor for FY2025: 56.15M for, 27K against.
Advisory vote on executive compensation approved: 53.2M for, 1.15M against.
Advisory vote favors 1-year frequency for future say-on-pay votes: 54.0M for 1 year.
59.2M shares outstanding, 56.2M present at meeting; broker non-votes of 1.87M.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.